Cas:98640-00-7 2-(5,6-dichloro-1H-indol-3-yl)acetic acid manufacturer & supplier

We serve Chemical Name:2-(5,6-dichloro-1H-indol-3-yl)acetic acid CAS:98640-00-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-(5,6-dichloro-1H-indol-3-yl)acetic acid

Chemical Name:2-(5,6-dichloro-1H-indol-3-yl)acetic acid
CAS.NO:98640-00-7
Synonyms:5,6-dichloroindole-3-acetic acid;1H-Indole-3-acetic acid,5,6-dichloro
Molecular Formula:C10H7Cl2NO2
Molecular Weight:244.07400
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:53.09000
Exact Mass:242.98500
LogP:3.10180

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5,6-dichloroindole-3-acetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Indole-3-acetic acid,5,6-dichloro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indole-3-acetic acid,5,6-dichloro Use and application,5,6-dichloroindole-3-acetic acid technical grade,usp/ep/jp grade.


Related News: This includes chemical APIs. 2-(5,6-dichloro-1H-indol-3-yl)acetic acid manufacturer A new case of coronavirus has been reported in the United Arab Emirates, the country’s fifth, the Ministry of Health and Prevention announced on Saturday. 2-(5,6-dichloro-1H-indol-3-yl)acetic acid supplier In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 2-(5,6-dichloro-1H-indol-3-yl)acetic acid vendor This includes chemical APIs. 2-(5,6-dichloro-1H-indol-3-yl)acetic acid factory International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.